随着跨国药企陆续披露2025年业绩报告,全球制药行业的新一轮竞争格局逐步清晰。 业绩榜单中,强生以全球941.93亿美元的总营收斩获榜首,旗下创新制药和医疗科技两大核心业务板块分别收入604.01亿美元(+6%)和337.92亿美元(+6.1%);礼来凭借44%的高增速,实现651.79亿美元的全年营收,成为增速最快的头部药企。此外,赛诺菲、诺华、阿斯利康、艾伯维等头部企业营收均保持上升趋势,...
Source Link随着跨国药企陆续披露2025年业绩报告,全球制药行业的新一轮竞争格局逐步清晰。 业绩榜单中,强生以全球941.93亿美元的总营收斩获榜首,旗下创新制药和医疗科技两大核心业务板块分别收入604.01亿美元(+6%)和337.92亿美元(+6.1%);礼来凭借44%的高增速,实现651.79亿美元的全年营收,成为增速最快的头部药企。此外,赛诺菲、诺华、阿斯利康、艾伯维等头部企业营收均保持上升趋势,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.